Literature DB >> 11756976

Altered synthesis of interleukin-12 and type 1 and type 2 cytokinesin rhesus macaques during measles and atypical measles.

Fernando P Polack1, Scott J Hoffman, William J Moss, Diane E Griffin.   

Abstract

Immunosuppression during and after measles results in increased susceptibility to other infections and 1 million deaths annually. The mechanism by which measles virus (MV) induces immune suppression is incompletely understood, but a type 2 skewing of the cytokine response after infection has been documented. In vitro studies suggest that lack of interleukin (IL)-12 production by monocytes and dendritic cells plays an early role in the skewed response. In addition, immunization with an inactivated measles vaccine before measles develops appears to lead to an even stronger type 2 skewing of the cytokine response and atypical measles. In this study, the cytokine responses in rhesus macaques were compared after vaccination with live and formalin-inactivated vaccines and after challenge with MV. In vivo production of IL-12 was decreased during the viremic phase of the illness, and production of IL-4 was increased during and after atypical measles, compared with measles.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11756976     DOI: 10.1086/338009

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response.

Authors:  Ianko D Iankov; Manoj Pandey; Mary Harvey; Guy E Griesmann; Mark J Federspiel; Stephen J Russell
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins.

Authors:  Man Ki Song; Christofer J Vindurampulle; Alejandra V E Capozzo; Jeffrey Ulmer; John M Polo; Marcela F Pasetti; Eileen M Barry; Myron M Levine
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection.

Authors:  Rik L De Swart; Thijs Kuiken; Helga H Timmerman; Geert van Amerongen; Bernadette G Van Den Hoogen; Helma W Vos; Herman J Neijens; Arno C Andeweg; Albert D M E Osterhaus
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 4.  Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.

Authors:  Barney S Graham
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 5.  Measles virus-induced immunosuppression: from effectors to mechanisms.

Authors:  Elita Avota; Evelyn Gassert; Sibylle Schneider-Schaulies
Journal:  Med Microbiol Immunol       Date:  2010-04-08       Impact factor: 3.402

6.  Measles virus hemagglutinin triggers intracellular signaling in CD150-expressing dendritic cells and inhibits immune response.

Authors:  Olga Romanets-Korbut; Larysa M Kovalevska; Tsukasa Seya; Svetlana P Sidorenko; Branka Horvat
Journal:  Cell Mol Immunol       Date:  2015-06-15       Impact factor: 11.530

7.  Attenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys.

Authors:  Patricia Devaux; Gregory Hodge; Michael B McChesney; Roberto Cattaneo
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

8.  Vaccines against respiratory syncytial virus: The time has finally come.

Authors:  Barney S Graham
Journal:  Vaccine       Date:  2016-05-13       Impact factor: 3.641

9.  Cytokine imbalance after measles virus infection has no correlation with immune suppression.

Authors:  Mary Carsillo; Kay Klapproth; Stefan Niewiesk
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

10.  Sang Froid in a time of trouble: is a vaccine against HIV possible?

Authors:  Stanley A Plotkin
Journal:  J Int AIDS Soc       Date:  2009-02-02       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.